228 related articles for article (PubMed ID: 30741995)
1. Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells.
Lee YJ; Chang WW; Chang CP; Liu TY; Chuang CY; Qian K; Zheng YG; Li C
Sci Rep; 2019 Feb; 9(1):1771. PubMed ID: 30741995
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma.
Eberhardt A; Hansen JN; Koster J; Lotta LT; Wang S; Livingstone E; Qian K; Valentijn LJ; Zheng YG; Schor NF; Li X
Oncotarget; 2016 Sep; 7(39):63629-63639. PubMed ID: 27571165
[TBL] [Abstract][Full Text] [Related]
3. Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.
Carr-Wilkinson J; Griffiths R; Elston R; Gamble LD; Goranov B; Redfern CP; Lunec J; Tweddle DA
Cell Cycle; 2011 Nov; 10(21):3778-87. PubMed ID: 22052359
[TBL] [Abstract][Full Text] [Related]
4. Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Altan B; Yokobori T; Ide M; Mochiki E; Toyomasu Y; Kogure N; Kimura A; Hara K; Bai T; Bao P; Suzuki M; Ogata K; Asao T; Nishiyama M; Oyama T; Kuwano H
Gastric Cancer; 2016 Jul; 19(3):789-97. PubMed ID: 26472729
[TBL] [Abstract][Full Text] [Related]
5. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
6. The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1.
Gao Y; Zhao Y; Zhang J; Lu Y; Liu X; Geng P; Huang B; Zhang Y; Lu J
Sci Rep; 2016 Jan; 6():19874. PubMed ID: 26813495
[TBL] [Abstract][Full Text] [Related]
7. PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells.
Chuang CY; Chang CP; Lee YJ; Lin WL; Chang WW; Wu JS; Cheng YW; Lee H; Li C
Oncol Rep; 2017 Aug; 38(2):1115-1123. PubMed ID: 28656289
[TBL] [Abstract][Full Text] [Related]
8. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.
Bell E; Premkumar R; Carr J; Lu X; Lovat PE; Kees UR; Lunec J; Tweddle DA
Cell Cycle; 2006 Nov; 5(22):2639-47. PubMed ID: 17172827
[TBL] [Abstract][Full Text] [Related]
9. PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma.
Feng G; Chen C; Luo Y
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859611
[TBL] [Abstract][Full Text] [Related]
10. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
[TBL] [Abstract][Full Text] [Related]
11. PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin.
Musiani D; Giambruno R; Massignani E; Ippolito MR; Maniaci M; Jammula S; Manganaro D; Cuomo A; Nicosia L; Pasini D; Bonaldi T
Cell Rep; 2020 Jan; 30(4):1208-1222.e9. PubMed ID: 31995759
[TBL] [Abstract][Full Text] [Related]
12. The role of protein arginine-methyltransferase 1 in gliomagenesis.
Wang S; Tan X; Yang B; Yin B; Yuan J; Qiang B; Peng X
BMB Rep; 2012 Aug; 45(8):470-5. PubMed ID: 22917032
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
Mazar J; Rosado A; Shelley J; Marchica J; Westmoreland TJ
Oncotarget; 2017 Jan; 8(4):6589-6607. PubMed ID: 28035057
[TBL] [Abstract][Full Text] [Related]
14. Deep Protein Methylation Profiling by Combined Chemical and Immunoaffinity Approaches Reveals Novel PRMT1 Targets.
Hartel NG; Chew B; Qin J; Xu J; Graham NA
Mol Cell Proteomics; 2019 Nov; 18(11):2149-2164. PubMed ID: 31451547
[TBL] [Abstract][Full Text] [Related]
15. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
[TBL] [Abstract][Full Text] [Related]
17. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
18. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
[TBL] [Abstract][Full Text] [Related]
19. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
[TBL] [Abstract][Full Text] [Related]
20. The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
Cattelani S; Ferrari-Amorotti G; Galavotti S; Defferrari R; Tanno B; Cialfi S; Vergalli J; Fragliasso V; Guerzoni C; Manzotti G; Soliera AR; Menin C; Bertorelle R; McDowell HP; Inserra A; Belli ML; Varesio L; Tweddle D; Tonini GP; Altavista P; Dominici C; Raschellà G; Calabretta B
Neoplasia; 2012 Jul; 14(7):634-43. PubMed ID: 22904680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
